Regarding the opinion that Poziotinib's clinical results are not enough to support prompt approval in a briefing released by the U.S. FDA on the 20th (local time) ahead of the Oncology Drug Advisory Committee (ODAC), Hanmi Pharmaceutical said, "We will fully explain the usefulness of Poziotinib at the ODAC scheduled for the 22nd." Poziotinib is considered an innovative treatment that can play a sufficient role as one of various treatment options for patients with HER2 Exon20 mutated non-small cell lung cancer who do not have a suitable treatment so far.

The adverse reactions reported so far are cases that appear in other drugs, and it is not only sufficiently manageable, but it is also observed that the